Key result
Routine screening for depression in patients with coronary heart disease is supported by evidence, and treatment with selective serotonin reuptake inhibitors is safe and can improve medical adherence.
Routine screening for depression in patients with CHD is recommended, as SSRIs are safe and can improve both depressive symptoms and adherence to cardiovascular medications.
Answers are grounded in this paper and cite their sources.
Supports depression screening and SSRI use in CHD; leaves open need for RCTs to confirm adherence benefits.
The American Heart Association issued a science advisory on depression and coronary heart disease (CHD) in 2008. This paper reviews the purpose and content of the advisory and discusses reactions and new information that have followed the advisory's release. Both the advisory and subsequent data support routine screening for depression in patients with CHD. Such screening can be done efficiently in primary care and cardiology settings and can effectively identify many depressed patients who would otherwise go undetected. Antidepressant drugs such as selective serotonin reuptake inhibitors are safe for use in patients with CHD, can reduce depression, and can improve adherence with medical therapy. Referral to a practice with the knowledge and resources to manage depression promotes successful management of depressed patients with CHD.
No takes yet. Share an insight, caveat, or question.
Bigger et al. (2010) conducted a review in Depression and Coronary Heart Disease. Routine screening and treatment for depression was evaluated. Routine screening for depression in patients with coronary heart disease is supported by evidence, and treatment with selective serotonin reuptake inhibitors is safe and can improve medical adherence.
Synapse has enriched 10 related papers. Consider them for comparative context: